Patient Characteristics at Time of Seizure Diagnosis
| Case | Center | Age (y) | Sex | Diagnosis | Tumor localization | Treatment | Disease status | Seizure disorder before |
| 1 + 2* | F | 64 | F | AA (1989) | Right frontal | SU, RA, CT 1989 | SD, no residual tumor | Yes (motor SPS, TCS) |
| 3 | R | 66 | F | O (1985) | Right frontal | SU, RA, PCV 1985 | SD, no residual tumor | Yes (motor SPS) |
| 4 | S | 44 | M | A (1991) | Left frontotemporal | SU 1991, 1996, 1997 | SD, no residual tumor | Yes (TCS) |
| OA (1996) | RA/BCNU 1997 | |||||||
| AOA (1997) | ||||||||
| 5 | R | 54 | M | A (2014) | Left frontoparietal | SU, TMZ 2014 | PD of residual tumor | Yes (motor SPS) |
| 6 | S | 68 | F | O (2004) | Right frontal | SU 2004 | SD, residual tumor | Yes (motor SPS, TCS) |
| AO (2011) | SU, RA/TMZ 05/2011 | |||||||
| CCNU 11/2011 | ||||||||
| 7 | R | 51 | M | GBM (2013) | Right frontal | SU 2013 | ID of GBM | Yes (CPS, TCS) |
| 8 | R | 29 | F | A (2012) | Right frontoparietal | SU 2012, TMZ 2012–2013 | PD of residual tumor | Yes (motor/sensory SPS, TCS) |
| sGBM (2015) | SU + RA/TMZ 2015 | |||||||
| 9 | R | 45 | M | AO (2012) | Right frontotemporal | SU, RA/TMZ 2012 | SD, residual tumor | No |
| PC 2014 | ||||||||
| BEV/CCNU 2014–2015 | ||||||||
| 10 | R | 76 | F | Nonconvulsive SE caused by septic encephalopathy (6/2013) | Anticonvulsive treatment | No recovery | Yes (nonconvulsive SE 4/2013) | |
| 11 | S | 66 | F | Embolic cerebral ischemia (2011) | Anticonvulsive treatment | Seizure-free after 1 d | No |
↵* Patient presented with same clinical symptoms and EEG findings according to SE in 2011 and 2014. At both time points combined MRI and 18F-FET PET imaging was available.
F = Freiburg, Germany; R = Regensburg, Germany; S = Salzburg, Austria; O = oligodendroglioma WHO II; A = astrocytoma WHO II; OA = oligoastrocytoma WHO II; AA = anaplastic astrocytoma WHO III; AOA = anaplastic oligoastrocytoma WHO III; AO = anaplastic oligodendroglioma WHO III; GBM = glioblastoma WHO IV (s, secondary); SU = surgery; RA = radiotherapy; TMZ = temozolomide; BCNU = carmustine; CCNU = lomustine; PC = procarbazine + CCNU; PCV = procarbazine + CCNU + vincristine; BEV = bevacizumab; SD = stable disease; PD = progressive disease; ID = initial diagnosis.